---
title: Intestinal pump reduces involuntary movements
nct_id: NCT07313176
status: RECRUITING
sponsor: Britannia Pharmaceuticals Ltd.
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07313176"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07313176"
last_fetched: "2026-05-10T14:02:12.316Z"
source: "Parkinson's Pathways (curated)"
---
# Intestinal pump reduces involuntary movements

**Goal (in five words):** Intestinal pump reduces involuntary movements

**Official Title:** A Prospective, Non-Interventional Study on the Long-term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIGON®) in Patients With Parkinson's Disease Previously Treated With Subcutaneous Foslevodopa in Routine Care

**Trial ID:** [NCT07313176](https://clinicaltrials.gov/study/NCT07313176)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Britannia Pharmaceuticals Ltd.
- **Target Enrollment:** 215 participants
- **Start Date:** 2026-01
- **Completion Date:** 2028-10
- **Conditions:** Advanced Parkinson Disease
- **Interventions:** No Intervention
- **Intervention Types:** OTHER

## Summary For Families

The goal is to see whether LECIGON, a levodopa‑entacapone‑carbidopa intestinal gel, gives lasting control of motor fluctuations and dyskinesia in people with advanced Parkinson's who previously used subcutaneous foslevodopa. LECIGON is delivered continuously by a pump into the intestine, it supplies levodopa with carbidopa to prevent peripheral breakdown and entacapone to block COMT so levodopa stays active longer and blood levels are smoother, which can reduce off time and troublesome involuntary movements. The study is enrolling adults 18 and older with advanced Parkinson's and severe motor fluctuations or dyskinesia who a physician has decided to start on LECIGON and who have used subcutaneous foslevodopa for at least one month, while those with LECIGON contraindications, inability to manage pump therapy, severe dementia or substance misuse, or in another interventional trial are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Adult participants (18 years old and over) with advanced Parkinson's disease with severe motor fluctuations and dyskinesia
* Participants for whom the treating physician has made the decision to initiate treatment with LECIGON® in accordance with the Summary of Product Characteristics (SmPC)
* Participants must have had previous treatment with subcutaneous foslevodopa (foslevodopa-foscarbidopa) for a minimum of 1 month
* Participants or legal representative must have signed informed consent to participate in the study

Exclusion Criteria:

* Participants with contraindications as defined in the current version of the SmPC for LECIGON®
* Participants who will not be seen again for their follow up care at the investigator's site after commencement of LECIGON® therapy
* Participants with anticipated pump placement or pump use issues, e.g. participants with acute severe illness, participants unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse
* Participants taking part in a clinical (interventional) trial at the same time
```

## Locations (2)

- Virgen del Rocío University Hospital, Seville, Av. Manuel Siurot, S/n, Spain _(37.3828, -5.9732)_
  - Sukhdeep Singh, MSci — (CONTACT)
- Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain _(43.3713, -8.3960)_
  - Sukhdeep Singh, MSc — (CONTACT) — +44 0118920950 — Sukhdeep.Singh@Britannia-pharm.com

## Central Contacts

- Sukhdeep Singh, MSci — (CONTACT) — +44 07954751548 — Sukhdeep.singh@britannia-pharm.com
- Niall Smith, MBA — (CONTACT) — Niall.smith@britannia-pharm.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07313176*  
*HTML version: https://parkinsonspathways.com/trial/NCT07313176*  
*Source data: https://clinicaltrials.gov/study/NCT07313176*